Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63


Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer.

Nakayama Y, Torigoe T, Inoue Y, Minagawa N, Izumi H, Kohno K, Yamaguchi K.

Exp Ther Med. 2012 Jan;3(1):25-30. Epub 2011 Oct 7.


Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor.

Gotanda Y, Akagi Y, Kawahara A, Kinugasa T, Yoshida T, Ryu Y, Shiratsuchi I, Kage M, Shirouzu K.

Anticancer Res. 2013 Jul;33(7):2941-7.


Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder.

Choi JW, Kim Y, Lee JH, Kim YS.

Urology. 2014 Jul;84(1):245.e9-15. doi: 10.1016/j.urology.2014.03.031. Epub 2014 May 22.


Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.

Doyen J, Trastour C, Ettore F, Peyrottes I, Toussant N, Gal J, Ilc K, Roux D, Parks SK, Ferrero JM, Pouysségur J.

Biochem Biophys Res Commun. 2014 Aug 15;451(1):54-61. doi: 10.1016/j.bbrc.2014.07.050. Epub 2014 Jul 21.


Clinical significance of mitochondrial transcription factor A expression in patients with colorectal cancer.

Nakayama Y, Yamauchi M, Minagawa N, Torigoe T, Izumi H, Kohno K, Yamaguchi K.

Oncol Rep. 2012 May;27(5):1325-30. doi: 10.3892/or.2012.1640. Epub 2012 Jan 16.


Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma.

Ohno A, Yorita K, Haruyama Y, Kondo K, Kato A, Ohtomo T, Kawaguchi M, Marutuska K, Chijiiwa K, Kataoka H.

Liver Int. 2014 Jul;34(6):942-52. doi: 10.1111/liv.12466. Epub 2014 Feb 7.


Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4.

Meijer TW, Schuurbiers OC, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, Verhagen AF, Lok J, van der Heijden HF, Rademakers SE, Span PN, Bussink J.

Lung Cancer. 2012 Jun;76(3):316-23. doi: 10.1016/j.lungcan.2011.11.006. Epub 2011 Dec 6.


Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.

Curry JM, Tuluc M, Whitaker-Menezes D, Ames JA, Anantharaman A, Butera A, Leiby B, Cognetti DM, Sotgia F, Lisanti MP, Martinez-Outschoorn UE.

Cell Cycle. 2013 May 1;12(9):1371-84. doi: 10.4161/cc.24092. Epub 2013 Apr 10.


Prognostic and survival analysis of 837 Chinese colorectal cancer patients.

Yuan Y, Li MD, Hu HG, Dong CX, Chen JQ, Li XF, Li JJ, Shen H.

World J Gastroenterol. 2013 May 7;19(17):2650-9. doi: 10.3748/wjg.v19.i17.2650.


Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma.

Yamanashi T, Nakanishi Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y, Watanabe M, Hirohashi S.

Oncology. 2009;77(1):53-62. doi: 10.1159/000226112. Epub 2009 Jun 25.


Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer.

Pértega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F.

BMC Cancer. 2011 Jul 25;11:312. doi: 10.1186/1471-2407-11-312.


The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer.

Pinheiro C, Longatto-Filho A, Simões K, Jacob CE, Bresciani CJ, Zilberstein B, Cecconello I, Alves VA, Schmitt F, Baltazar F.

Eur J Cancer. 2009 Sep;45(13):2418-24. doi: 10.1016/j.ejca.2009.06.018. Epub 2009 Jul 21.


Stromal-epithelial metabolic coupling in gastric cancer: stromal MCT4 and mitochondrial TOMM20 as poor prognostic factors.

Zhao Z, Han F, He Y, Yang S, Hua L, Wu J, Zhan W.

Eur J Surg Oncol. 2014 Oct;40(10):1361-8. doi: 10.1016/j.ejso.2014.04.005. Epub 2014 Apr 28.


DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.

Fisel P, Kruck S, Winter S, Bedke J, Hennenlotter J, Nies AT, Scharpf M, Fend F, Stenzl A, Schwab M, Schaeffeler E.

Clin Cancer Res. 2013 Sep 15;19(18):5170-81. doi: 10.1158/1078-0432.CCR-13-1180. Epub 2013 Jul 23.


Clinical significance of perineural invasion in stages II and III colorectal cancer.

Zhou Y, Wang H, Gong H, Cao M, Zhang G, Wang Y.

Pathol Res Pract. 2015 Nov;211(11):839-44. doi: 10.1016/j.prp.2015.09.001. Epub 2015 Sep 4.


Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.

Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, Sneddon S, Martinez-Outschoorn UE, Sotgia F, Lisanti MP.

Cell Cycle. 2012 Mar 15;11(6):1108-17. doi: 10.4161/cc.11.6.19530. Epub 2012 Mar 15.


The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells.

Dimmer KS, Friedrich B, Lang F, Deitmer JW, Bröer S.

Biochem J. 2000 Aug 15;350 Pt 1:219-27.


Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer.

Zhang P, Ji DB, Han HB, Shi YF, Du CZ, Gu J.

World J Gastroenterol. 2014 Sep 14;20(34):12241-8. doi: 10.3748/wjg.v20.i34.12241.


RacGAP1 expression, increasing tumor malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer.

Imaoka H, Toiyama Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, Tanaka K, Inoue Y, Mohri Y, Kusunoki M.

Carcinogenesis. 2015 Mar;36(3):346-54. doi: 10.1093/carcin/bgu327. Epub 2015 Jan 7.


Supplemental Content

Support Center